KNW
REGN icon

Kesler Norman & Wride’s Regeneron Pharmaceuticals REGN Stock Holding History

Kesler Norman & Wride’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-443
Closed -$316K – 258
2025
Q3 		$316K Buy
+443
New +$250K 0.06% 199
2025
Q1 		– Sell
-443
Closed -$316K – 220
2024
Q4 		$316K Buy
+443
New +$372K 0.07% 194

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kesler Norman & Wride's REGN Position: Q4 2025 in Review

Kesler Norman & Wride sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 443 shares — an estimated $316K sold.

Kesler Norman & Wride first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $316K in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Kesler Norman & Wride reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Kesler Norman & Wride sold 443 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $316K.
  • Kesler Norman & Wride first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Kesler Norman & Wride's Regeneron Pharmaceuticals position peaked at $316K in Q3 2025.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Kesler Norman & Wride's 13F filing for Q4 2025, filed 10 Feb 2026.